hMAO-B/MB-COMT-IN-2 

hMAO-B/MB-COMT-IN-2 is a dual MAO-B/MB-COMT inhibitor (IC₅₀s: 4.27 μΜ for hMAO-B, 2.69 μΜ for MB-COMT). hMAO-B/MB-COMT-IN-2 protects cells against oxidative damage. hMAO-B/MB-COMT-IN-2 can be used in the research of neurodegeneration disease, such as Parkinson’s Disease (PD)^[1].

hMAO-B/MB-COMT-IN-2 (compound 8, 50 μM, 24 h) decreases in resazurin reduction in differentiated SH-SY5Y cells^[1].
hMAO-B/MB-COMT-IN-2 (50 μM, 24 h) displays lysosomal toxicity by producing ROS in differentiated SH-SY5Y cells^[1].
hMAO-B/MB-COMT-IN-2 (10 μM, 30 min) displays remarkable cytoprotective effects against t-BHP in differentiated SH-SY5Y cells^[1].
hMAO-B/MB-COMT-IN-2 is predicted to cross the blood-brain barrier (BBB) by passive diffusion, determined by the parallel artificial membrane permeability assay (PAMPA)-BBB kit^[1].
hMAO-B/MB-COMT-IN-2 (30-50 μM, 24 h) has good safety profile in SK-N-SH cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

298.34

C₁₇H₁₈N₂O₃

3033106-46-3

OC1=CC(/C=C/C=C(C#N)\C(N2CCCCC2)=O)=CC=C1O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Daniel Chavarria, et al. Boosting caffeic acid performance as antioxidant and monoamine oxidase B/catechol-O-methyltransferase inhibitor. Eur J Med Chem. 2022 Sep 8;243:114740.  [Content Brief]